BR112019013954A2 - Métodos para o tratamento de distúrbios neurológicos - Google Patents
Métodos para o tratamento de distúrbios neurológicos Download PDFInfo
- Publication number
- BR112019013954A2 BR112019013954A2 BR112019013954-0A BR112019013954A BR112019013954A2 BR 112019013954 A2 BR112019013954 A2 BR 112019013954A2 BR 112019013954 A BR112019013954 A BR 112019013954A BR 112019013954 A2 BR112019013954 A2 BR 112019013954A2
- Authority
- BR
- Brazil
- Prior art keywords
- group
- alkyl
- independently selected
- formula
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 325
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 35
- 208000025966 Neurological disease Diseases 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 467
- 239000003112 inhibitor Substances 0.000 claims description 292
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 230000001988 toxicity Effects 0.000 claims description 16
- 231100000419 toxicity Toxicity 0.000 claims description 16
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 101100041816 Homo sapiens SCD gene Proteins 0.000 claims description 12
- 101000639987 Homo sapiens Stearoyl-CoA desaturase 5 Proteins 0.000 claims description 12
- 101150097713 SCD1 gene Proteins 0.000 claims description 12
- 102100033930 Stearoyl-CoA desaturase 5 Human genes 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 7
- 238000004220 aggregation Methods 0.000 claims description 7
- 210000003061 neural cell Anatomy 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
- 230000004845 protein aggregation Effects 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000032859 Synucleinopathies Diseases 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000011403 Alexander disease Diseases 0.000 claims description 3
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 3
- 102000007371 Ataxin-3 Human genes 0.000 claims description 3
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 3
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims description 3
- 208000010200 Cockayne syndrome Diseases 0.000 claims description 3
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 3
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 claims description 3
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000027747 Kennedy disease Diseases 0.000 claims description 3
- 208000028226 Krabbe disease Diseases 0.000 claims description 3
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 208000005587 Refsum Disease Diseases 0.000 claims description 3
- 208000021811 Sandhoff disease Diseases 0.000 claims description 3
- 208000021235 Schilder disease Diseases 0.000 claims description 3
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 3
- 208000030597 adult Refsum disease Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000002040 neurosyphilis Diseases 0.000 claims description 3
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 230000012846 protein folding Effects 0.000 claims description 3
- 208000002025 tabes dorsalis Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000022526 Canavan disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000015872 Gaucher disease Diseases 0.000 claims description 2
- 108010021592 Pantothenate kinase Proteins 0.000 claims description 2
- 102100024122 Pantothenate kinase 1 Human genes 0.000 claims description 2
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 claims description 2
- 208000009144 Pure autonomic failure Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 239000000164 antipsychotic agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 210000004558 lewy body Anatomy 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical group 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 108010025628 Apolipoproteins E Proteins 0.000 claims 3
- 102000013918 Apolipoproteins E Human genes 0.000 claims 3
- 102000003802 alpha-Synuclein Human genes 0.000 claims 3
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 2
- 208000036022 Alpers' disease Diseases 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 206010063491 Herpes zoster oticus Diseases 0.000 claims 1
- 208000006136 Leigh Disease Diseases 0.000 claims 1
- 208000017507 Leigh syndrome Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 claims 1
- 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 239000002664 nootropic agent Substances 0.000 claims 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 description 354
- 229910052739 hydrogen Inorganic materials 0.000 description 338
- 239000001257 hydrogen Substances 0.000 description 336
- -1 C4-Ci2cicloalkyl Chemical group 0.000 description 285
- 125000001072 heteroaryl group Chemical group 0.000 description 283
- 125000003118 aryl group Chemical group 0.000 description 256
- 125000000753 cycloalkyl group Chemical group 0.000 description 232
- 125000001153 fluoro group Chemical group F* 0.000 description 225
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 211
- 229910052736 halogen Inorganic materials 0.000 description 202
- 150000002367 halogens Chemical class 0.000 description 202
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 199
- 125000000623 heterocyclic group Chemical group 0.000 description 197
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 164
- 235000019000 fluorine Nutrition 0.000 description 150
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 138
- 125000001424 substituent group Chemical group 0.000 description 119
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 112
- 150000003839 salts Chemical class 0.000 description 108
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 96
- 125000003710 aryl alkyl group Chemical group 0.000 description 88
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 76
- 125000004093 cyano group Chemical group *C#N 0.000 description 70
- 239000000460 chlorine Substances 0.000 description 66
- 229910052801 chlorine Inorganic materials 0.000 description 66
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 64
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 64
- 229910052731 fluorine Inorganic materials 0.000 description 63
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 63
- 239000011737 fluorine Substances 0.000 description 62
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 61
- 125000003342 alkenyl group Chemical group 0.000 description 60
- 125000003545 alkoxy group Chemical group 0.000 description 58
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 57
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 57
- 229910052794 bromium Inorganic materials 0.000 description 57
- 229910052799 carbon Inorganic materials 0.000 description 51
- 229910052717 sulfur Inorganic materials 0.000 description 51
- 229910052760 oxygen Inorganic materials 0.000 description 49
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 48
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 47
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 46
- 125000001624 naphthyl group Chemical group 0.000 description 46
- 150000001721 carbon Chemical group 0.000 description 38
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 38
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 38
- 125000004043 oxo group Chemical group O=* 0.000 description 38
- 239000002253 acid Substances 0.000 description 37
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 36
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 34
- 125000004429 atom Chemical group 0.000 description 33
- 125000001188 haloalkyl group Chemical group 0.000 description 32
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 30
- 125000005843 halogen group Chemical group 0.000 description 30
- 125000000304 alkynyl group Chemical group 0.000 description 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 28
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 28
- 239000000651 prodrug Substances 0.000 description 28
- 229940002612 prodrug Drugs 0.000 description 28
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 26
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 25
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 23
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 23
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 22
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 22
- 229920000728 polyester Polymers 0.000 description 22
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 21
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 125000002947 alkylene group Chemical group 0.000 description 20
- 125000001309 chloro group Chemical group Cl* 0.000 description 20
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 19
- 125000005842 heteroatom Chemical group 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 17
- 125000002950 monocyclic group Chemical group 0.000 description 17
- 125000003282 alkyl amino group Chemical group 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- QBPUOAJBMXXBNU-UHFFFAOYSA-N 3-phenyl-1H-pyrazole-5-carboxylic acid Chemical compound N1C(C(=O)O)=CC(C=2C=CC=CC=2)=N1 QBPUOAJBMXXBNU-UHFFFAOYSA-N 0.000 description 14
- 125000004450 alkenylene group Chemical group 0.000 description 14
- 229940080818 propionamide Drugs 0.000 description 14
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 13
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 13
- 125000004076 pyridyl group Chemical group 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 description 12
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 10
- 125000002883 imidazolyl group Chemical group 0.000 description 10
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 229940032147 starch Drugs 0.000 description 10
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 9
- DSIBSRXKQRYPJP-UHFFFAOYSA-N 1,2-oxazole-5-carboxamide Chemical compound NC(=O)C1=CC=NO1 DSIBSRXKQRYPJP-UHFFFAOYSA-N 0.000 description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 150000003857 carboxamides Chemical class 0.000 description 9
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 9
- 125000001544 thienyl group Chemical group 0.000 description 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 8
- 125000000335 thiazolyl group Chemical group 0.000 description 8
- 241000670727 Amida Species 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000001769 aryl amino group Chemical group 0.000 description 7
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 7
- 125000001786 isothiazolyl group Chemical group 0.000 description 7
- 125000000842 isoxazolyl group Chemical group 0.000 description 7
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 6
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 125000004419 alkynylene group Chemical group 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 125000004663 dialkyl amino group Chemical group 0.000 description 6
- 125000004986 diarylamino group Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 6
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 6
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 5
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 5
- UJWBFVKKNZXICC-UHFFFAOYSA-N 2-amino-1-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)CN)CCC1OC1=CC=CC(C(F)(F)F)=C1 UJWBFVKKNZXICC-UHFFFAOYSA-N 0.000 description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 5
- 102100026882 Alpha-synuclein Human genes 0.000 description 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 description 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 4
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 4
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 4
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 4
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- GTODOEDLCNTSLG-UHFFFAOYSA-N 2h-triazole-4-carboxylic acid Chemical compound OC(=O)C1=CNN=N1 GTODOEDLCNTSLG-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
- 108010087894 Fatty acid desaturases Proteins 0.000 description 4
- 238000004965 Hartree-Fock calculation Methods 0.000 description 4
- 241001024304 Mino Species 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 150000003852 triazoles Chemical class 0.000 description 4
- 229910052720 vanadium Inorganic materials 0.000 description 4
- CVCYZCBJCQXUCN-UHFFFAOYSA-N 1,2-oxazol-4-amine Chemical compound NC=1C=NOC=1 CVCYZCBJCQXUCN-UHFFFAOYSA-N 0.000 description 3
- JWAWEQBUZOGIBZ-UHFFFAOYSA-N 1-methyltriazole Chemical compound CN1C=CN=N1 JWAWEQBUZOGIBZ-UHFFFAOYSA-N 0.000 description 3
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 3
- 206010029240 Neuritis Diseases 0.000 description 3
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 3
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- FPOLWERNILTNDK-UHFFFAOYSA-N pyruvamide Chemical compound CC(=O)C(N)=O FPOLWERNILTNDK-UHFFFAOYSA-N 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 3
- 125000006715 (C1-C5) alkylthio group Chemical group 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 2
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 2
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 2
- MIIQJAUWHSUTIT-UHFFFAOYSA-N 1,2-oxazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=NO1 MIIQJAUWHSUTIT-UHFFFAOYSA-N 0.000 description 2
- IVDBIFHDJPMBFG-UHFFFAOYSA-N 1-phenyltriazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1C1=CC=CC=C1 IVDBIFHDJPMBFG-UHFFFAOYSA-N 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 2
- SITIEWSXZYWOSZ-UHFFFAOYSA-N 2-amino-1-[4-(5-chloropyridin-3-yl)oxypiperidin-1-yl]ethanone Chemical compound C1CN(C(=O)CN)CCC1OC1=CN=CC(Cl)=C1 SITIEWSXZYWOSZ-UHFFFAOYSA-N 0.000 description 2
- OSKSVLBJJXQUPI-UHFFFAOYSA-N 2h-triazole-4-carboxamide Chemical compound NC(=O)C1=CNN=N1 OSKSVLBJJXQUPI-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- ZYFRBEJYRHBUSJ-UHFFFAOYSA-N C1CN(C(=O)CN)CCC1OC1=CC=CC=C1Cl Chemical compound C1CN(C(=O)CN)CCC1OC1=CC=CC=C1Cl ZYFRBEJYRHBUSJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 2
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 description 2
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OSTIHFXUTPZJQL-UHFFFAOYSA-N fluoro benzoate Chemical compound FOC(=O)C1=CC=CC=C1 OSTIHFXUTPZJQL-UHFFFAOYSA-N 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- KERBTFURRLPANO-UHFFFAOYSA-N n-[2-[4-[[4-amino-5-(2,6-difluorobenzoyl)-1,3-thiazol-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2SC(=C(N)N=2)C(=O)C=2C(=CC=CC=2F)F)=C1 KERBTFURRLPANO-UHFFFAOYSA-N 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- SHKXZIQNFMOPBS-OOMQYRRCSA-N (4r)-4-[(3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound O[C@H]1C[C@@H]2[C@@]3(C)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)C[C@H]3C[C@@H](O)[C@H]2[C@@H]2CC[C@H]([C@H](C)CCC(O)=O)[C@]21C SHKXZIQNFMOPBS-OOMQYRRCSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006694 (C2-C10) heterocyclyl group Chemical group 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 description 1
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 1
- DPDLVZSIELSTBG-UHFFFAOYSA-N 1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC=1C=NOC=1 DPDLVZSIELSTBG-UHFFFAOYSA-N 0.000 description 1
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- DCVWMMMKFZVEDP-UHFFFAOYSA-N 1-(cyclobutylmethyl)triazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1CC1CCC1 DCVWMMMKFZVEDP-UHFFFAOYSA-N 0.000 description 1
- PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 description 1
- SNDYICNMPKEAQO-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]-n-(3,4-dimethoxyphenyl)-5-methyltriazole-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)C1=C(C)N(CC=2C=CC(Br)=CC=2)N=N1 SNDYICNMPKEAQO-UHFFFAOYSA-N 0.000 description 1
- UUTNWIDAELOPML-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-[3-(hydroxymethyl)phenyl]-5-methyltriazole-4-carboxamide Chemical compound CC1=C(C(=O)NC=2C=C(CO)C=CC=2)N=NN1CC1=CC=C(F)C=C1 UUTNWIDAELOPML-UHFFFAOYSA-N 0.000 description 1
- FTZQOVNWUQXBAT-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-[4-(hydroxymethyl)phenyl]-5-methyltriazole-4-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(CO)=CC=2)N=NN1CC1=CC=C(F)C=C1 FTZQOVNWUQXBAT-UHFFFAOYSA-N 0.000 description 1
- ZGQNPVJKWGWDTA-UHFFFAOYSA-N 1-benzyl-n-[3-(hydroxymethyl)phenyl]-5-methyltriazole-4-carboxamide Chemical compound CC1=C(C(=O)NC=2C=C(CO)C=CC=2)N=NN1CC1=CC=CC=C1 ZGQNPVJKWGWDTA-UHFFFAOYSA-N 0.000 description 1
- 125000006018 1-methyl-ethenyl group Chemical group 0.000 description 1
- DBYLAWFMMVZTRR-UHFFFAOYSA-N 1-phenylimidazole-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CN1C1=CC=CC=C1 DBYLAWFMMVZTRR-UHFFFAOYSA-N 0.000 description 1
- CFLQPPVBAQNLTQ-UHFFFAOYSA-N 1-pyridin-3-yltriazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1C1=CC=CN=C1 CFLQPPVBAQNLTQ-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical compound C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- JWLBYNOERXCWJZ-UHFFFAOYSA-N 2-[3-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2,4-oxadiazol-5-yl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=CC(C=2ON=C(N=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=C1 JWLBYNOERXCWJZ-UHFFFAOYSA-N 0.000 description 1
- VJYMDTMHJYNRJZ-UHFFFAOYSA-N 2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-5-(2h-tetrazol-5-yl)-1,3,4-thiadiazole Chemical compound FC1=CC=C(Br)C(OC2CCN(CC2)C=2SC(=NN=2)C2=NNN=N2)=C1 VJYMDTMHJYNRJZ-UHFFFAOYSA-N 0.000 description 1
- UJEAABFSXKCSGI-UHFFFAOYSA-N 2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2ON=C(C=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 UJEAABFSXKCSGI-UHFFFAOYSA-N 0.000 description 1
- QHGRDLNGTTUCJI-UHFFFAOYSA-N 2-[5-[3-[4-(5-bromo-2-chlorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2ON=C(C=2)N2CCC(CC2)OC=2C(=CC=C(Br)C=2)Cl)=N1 QHGRDLNGTTUCJI-UHFFFAOYSA-N 0.000 description 1
- MEDUDQBUYOHPBU-UHFFFAOYSA-N 2-[5-[5-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2SC(=NN=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 MEDUDQBUYOHPBU-UHFFFAOYSA-N 0.000 description 1
- PLDBMKVHTSHIMR-UHFFFAOYSA-N 2-amino-1-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)CN)CCC1OC1=CC(F)=CC=C1Cl PLDBMKVHTSHIMR-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- GSFNQBFZFXUTBN-UHFFFAOYSA-N 2-chlorothiophene Chemical compound ClC1=CC=CS1 GSFNQBFZFXUTBN-UHFFFAOYSA-N 0.000 description 1
- FMJUQKZHSLNVNW-UHFFFAOYSA-N 3-(3-fluorophenyl)-1h-pyrazole-5-carboxylic acid Chemical compound N1N=C(C(=O)O)C=C1C1=CC=CC(F)=C1 FMJUQKZHSLNVNW-UHFFFAOYSA-N 0.000 description 1
- KOWRVFWZCLHEIU-UHFFFAOYSA-N 3-(3-hydroxyphenyl)-1h-pyrazole-5-carboxylic acid Chemical compound N1C(C(=O)O)=CC(C=2C=C(O)C=CC=2)=N1 KOWRVFWZCLHEIU-UHFFFAOYSA-N 0.000 description 1
- SENIBRBPGXJDBL-UHFFFAOYSA-N 3-[3-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]propanoic acid Chemical compound OC(=O)CCN1C=CC(C=2ON=C(N=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 SENIBRBPGXJDBL-UHFFFAOYSA-N 0.000 description 1
- PVMAVVKCBJVOIS-UHFFFAOYSA-N 3-[4-(2-aminophenoxy)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound NC1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 PVMAVVKCBJVOIS-UHFFFAOYSA-N 0.000 description 1
- LMTFETKUEHTGOQ-UHFFFAOYSA-N 3-[4-(2-bromoanilino)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound BrC1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 LMTFETKUEHTGOQ-UHFFFAOYSA-N 0.000 description 1
- CATCQUIDMCNBSP-UHFFFAOYSA-N 3-[4-(3-phenylpropoxy)phenyl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCCCC1=CC=CC=C1 CATCQUIDMCNBSP-UHFFFAOYSA-N 0.000 description 1
- UJYKHFQAQQJDEO-UHFFFAOYSA-N 3-[4-[(2,6-dichlorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3Cl)Cl)=CC=2)=N1 UJYKHFQAQQJDEO-UHFFFAOYSA-N 0.000 description 1
- RRXNRQZPVMFOIW-UHFFFAOYSA-N 3-[4-[(2,6-dimethylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC=CC(C)=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 RRXNRQZPVMFOIW-UHFFFAOYSA-N 0.000 description 1
- MAOXNLBTQNBATO-UHFFFAOYSA-N 3-[4-[(2-cyanophenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(COC=3C(=CC=CC=3)C#N)=CC=2)=N1 MAOXNLBTQNBATO-UHFFFAOYSA-N 0.000 description 1
- CVADAAIEZSWZGA-UHFFFAOYSA-N 3-[4-[(2-methoxyphenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound COC1=CC=CC=C1COC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 CVADAAIEZSWZGA-UHFFFAOYSA-N 0.000 description 1
- RFXSMIAGEBZIPP-UHFFFAOYSA-N 3-[4-[(2-tert-butylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC(C)(C)C1=CC=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 RFXSMIAGEBZIPP-UHFFFAOYSA-N 0.000 description 1
- WWPWATFOLIDRII-UHFFFAOYSA-N 3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(Cl)C(Cl)=C1 WWPWATFOLIDRII-UHFFFAOYSA-N 0.000 description 1
- HSHOURBGTONSMS-UHFFFAOYSA-N 3-[4-[[3-(trifluoromethoxy)phenyl]methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=CC(OC(F)(F)F)=C1 HSHOURBGTONSMS-UHFFFAOYSA-N 0.000 description 1
- QHPVHZFPPXSDKS-UHFFFAOYSA-N 3-[5-(2-phenylethoxy)pyridin-2-yl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(N=C1)=CC=C1OCCC1=CC=CC=C1 QHPVHZFPPXSDKS-UHFFFAOYSA-N 0.000 description 1
- DTEYXFXPLZRCQP-UHFFFAOYSA-N 3-[5-[(2-chlorophenyl)methoxy]pyridin-2-yl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2N=CC(OCC=3C(=CC=CC=3)Cl)=CC=2)=N1 DTEYXFXPLZRCQP-UHFFFAOYSA-N 0.000 description 1
- WGRPQCFFBRDZFV-UHFFFAOYSA-N 3-methylbenzamide Chemical compound CC1=CC=CC(C(N)=O)=C1 WGRPQCFFBRDZFV-UHFFFAOYSA-N 0.000 description 1
- ZBRDJMFLJXFIGJ-UHFFFAOYSA-N 3-phenyl-1,2-oxazole Chemical compound O1C=CC(C=2C=CC=CC=2)=N1 ZBRDJMFLJXFIGJ-UHFFFAOYSA-N 0.000 description 1
- VZCDZCUPZRFWAW-UHFFFAOYSA-N 3-pyridin-3-yl-1h-pyrazole-5-carboxylic acid Chemical compound N1C(C(=O)O)=CC(C=2C=NC=CC=2)=N1 VZCDZCUPZRFWAW-UHFFFAOYSA-N 0.000 description 1
- UJFZKWPBNXPXRR-UHFFFAOYSA-N 4-[3-(dimethylamino)phenyl]benzoic acid Chemical compound CN(C)C1=CC=CC(C=2C=CC(=CC=2)C(O)=O)=C1 UJFZKWPBNXPXRR-UHFFFAOYSA-N 0.000 description 1
- UDEZJEHEWOCUJZ-UHFFFAOYSA-N 4-anilinobenzamide Chemical compound C1=CC(C(=O)N)=CC=C1NC1=CC=CC=C1 UDEZJEHEWOCUJZ-UHFFFAOYSA-N 0.000 description 1
- GVSNQMFKEPBIOY-UHFFFAOYSA-N 4-methyl-2h-triazole Chemical compound CC=1C=NNN=1 GVSNQMFKEPBIOY-UHFFFAOYSA-N 0.000 description 1
- GPGKNEKFDGOXPO-UHFFFAOYSA-N 4-phenyl-1h-pyrazole Chemical compound C1=NNC=C1C1=CC=CC=C1 GPGKNEKFDGOXPO-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- UZFWPGDNEOHFBK-UHFFFAOYSA-N 5-(2-hydroxyphenyl)-1,2-oxazole-3-carboxylic acid Chemical compound O1N=C(C(=O)O)C=C1C1=CC=CC=C1O UZFWPGDNEOHFBK-UHFFFAOYSA-N 0.000 description 1
- BQKZGPWCYWHOSM-UHFFFAOYSA-N 5-(2-hydroxyphenyl)-1-methylpyrazole-3-carboxylic acid Chemical compound CN1N=C(C(O)=O)C=C1C1=CC=CC=C1O BQKZGPWCYWHOSM-UHFFFAOYSA-N 0.000 description 1
- JZCBQTRPILCIBC-UHFFFAOYSA-N 5-(4-fluorophenyl)-1,2-oxazole Chemical compound C1=CC(F)=CC=C1C1=CC=NO1 JZCBQTRPILCIBC-UHFFFAOYSA-N 0.000 description 1
- STTNBHIFTZEPSH-UHFFFAOYSA-N 5-(4-fluorophenyl)-1h-pyrazole Chemical compound C1=CC(F)=CC=C1C1=CC=NN1 STTNBHIFTZEPSH-UHFFFAOYSA-N 0.000 description 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
- CUVQWHXSWHVJRS-UHFFFAOYSA-N 5-methyl-2h-triazole-4-carboxamide Chemical compound CC=1NN=NC=1C(N)=O CUVQWHXSWHVJRS-UHFFFAOYSA-N 0.000 description 1
- XJYOBHXWBRKOQO-UHFFFAOYSA-N 5-phenyl-1,2-oxazole-3-carboxylic acid Chemical compound O1N=C(C(=O)O)C=C1C1=CC=CC=C1 XJYOBHXWBRKOQO-UHFFFAOYSA-N 0.000 description 1
- ZLLOWHFKKIOINR-UHFFFAOYSA-N 5-phenyl-1,3-thiazole Chemical compound S1C=NC=C1C1=CC=CC=C1 ZLLOWHFKKIOINR-UHFFFAOYSA-N 0.000 description 1
- USQCUKQZXOWUDF-YWZLYKJASA-N 6-chloro-n-[(3s)-1-[(2s)-1-(4-methyl-5-oxo-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide Chemical compound O=C([C@@H](N1C([C@@H](NS(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1)=O)C)N1CCN(C)C(=O)CC1 USQCUKQZXOWUDF-YWZLYKJASA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010060219 Apolipoprotein E2 Proteins 0.000 description 1
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 1
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 1
- FPGQAXHNTRRTEV-UHFFFAOYSA-N C1CN(C(=O)CN)CCC1OC1=CC(F)=C(F)C(F)=C1 Chemical compound C1CN(C(=O)CN)CCC1OC1=CC(F)=C(F)C(F)=C1 FPGQAXHNTRRTEV-UHFFFAOYSA-N 0.000 description 1
- YXBYJWAEBFINLK-UHFFFAOYSA-N C1CN(C(=O)CN)CCC1OC1=CC=CC(Cl)=C1 Chemical compound C1CN(C(=O)CN)CCC1OC1=CC=CC(Cl)=C1 YXBYJWAEBFINLK-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- QVGIFIDYKPMSJD-UHFFFAOYSA-N CC1=CC=C(C#N)C=C1OC1CN(C(=O)CN)C1 Chemical compound CC1=CC=C(C#N)C=C1OC1CN(C(=O)CN)C1 QVGIFIDYKPMSJD-UHFFFAOYSA-N 0.000 description 1
- GTDDPQQGUQSYCE-UHFFFAOYSA-N CC1=CC=CC=C1NC1CCN(C(=O)CN)CC1 Chemical compound CC1=CC=CC=C1NC1CCN(C(=O)CN)CC1 GTDDPQQGUQSYCE-UHFFFAOYSA-N 0.000 description 1
- 101100063435 Caenorhabditis elegans din-1 gene Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
- 101000957333 Homo sapiens Muscleblind-like protein 3 Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102100038751 Muscleblind-like protein 3 Human genes 0.000 description 1
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 1
- IVNVKOHCUFPXLK-UHFFFAOYSA-N NCC(N(CC1)CCC1OC1=C(C=NO)C=CC=C1)=O Chemical compound NCC(N(CC1)CCC1OC1=C(C=NO)C=CC=C1)=O IVNVKOHCUFPXLK-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101150048395 SCD gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- WJWWCJJDDLCVCA-UHFFFAOYSA-N amino carbonofluoridate Chemical compound NOC(F)=O WJWWCJJDDLCVCA-UHFFFAOYSA-N 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-N benzene-dicarboxylic acid Natural products OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
- 150000004802 benzothiophens Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910021386 carbon form Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- PSQJYQJRWKEMEC-UHFFFAOYSA-N chembl1327656 Chemical compound O1N=C(C(=O)O)C=C1C1=CC=C(O)C=C1 PSQJYQJRWKEMEC-UHFFFAOYSA-N 0.000 description 1
- VTXQMHBETSEFDV-UHFFFAOYSA-N chembl1567394 Chemical compound N1N=C(C(=O)O)C=C1C1=CC=CC=C1O VTXQMHBETSEFDV-UHFFFAOYSA-N 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 229960003887 dichlorophen Drugs 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 125000006333 difluoro benzoyl group Chemical group 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 229950002375 englitazone Drugs 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 description 1
- 102000053020 human ApoE Human genes 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- MZDGXTXYHXDWIM-UHFFFAOYSA-N methyl benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=CC=C1 MZDGXTXYHXDWIM-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- HOOPXRBWBDIVAT-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-1-[(4-fluorophenyl)methyl]-5-methyltriazole-4-carboxamide Chemical group C1=C(OC)C(OC)=CC=C1NC(=O)C1=C(C)N(CC=2C=CC(F)=CC=2)N=N1 HOOPXRBWBDIVAT-UHFFFAOYSA-N 0.000 description 1
- ZGLLLMOBKSCLOF-UHFFFAOYSA-N n-(3-acetamidophenyl)-1-[(3,4-dichlorophenyl)methyl]-5-methyltriazole-4-carboxamide Chemical compound CC(=O)NC1=CC=CC(NC(=O)C2=C(N(CC=3C=C(Cl)C(Cl)=CC=3)N=N2)C)=C1 ZGLLLMOBKSCLOF-UHFFFAOYSA-N 0.000 description 1
- UOUBPDZUBVJZOQ-UHFFFAOYSA-N n-(hydroxymethyl)benzamide Chemical compound OCNC(=O)C1=CC=CC=C1 UOUBPDZUBVJZOQ-UHFFFAOYSA-N 0.000 description 1
- GNSCZTQFUZQSLY-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-phenylpyrazole-4-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=CN(N=C2)C=2C=CC=CC=2)CC1 GNSCZTQFUZQSLY-UHFFFAOYSA-N 0.000 description 1
- LKWPGLCZVNYLPL-UHFFFAOYSA-N n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2C=CC(=CC=2)C(=O)N2CCCC2)=C1 LKWPGLCZVNYLPL-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 1
- QTAWENRCMMMZJC-UHFFFAOYSA-N oxadiazole;pyridazine Chemical group C1=CON=N1.C1=CC=NN=C1 QTAWENRCMMMZJC-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical group 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 101150034433 terC gene Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443066P | 2017-01-06 | 2017-01-06 | |
| US62/443,066 | 2017-01-06 | ||
| PCT/US2018/012697 WO2018129403A1 (en) | 2017-01-06 | 2018-01-05 | Methods for the treatment of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019013954A2 true BR112019013954A2 (pt) | 2020-02-11 |
Family
ID=62782012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019013954-0A BR112019013954A2 (pt) | 2017-01-06 | 2018-01-05 | Métodos para o tratamento de distúrbios neurológicos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10973810B2 (enExample) |
| EP (1) | EP3566055B1 (enExample) |
| JP (2) | JP2020514293A (enExample) |
| KR (1) | KR20190108118A (enExample) |
| CN (1) | CN110392833A (enExample) |
| AU (1) | AU2018205275B2 (enExample) |
| BR (1) | BR112019013954A2 (enExample) |
| CA (1) | CA3049010A1 (enExample) |
| EA (1) | EA201991650A1 (enExample) |
| ES (1) | ES3025460T3 (enExample) |
| IL (2) | IL304017A (enExample) |
| MA (1) | MA47212A (enExample) |
| MX (1) | MX2019008124A (enExample) |
| WO (1) | WO2018129403A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019533022A (ja) * | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| CA3049010A1 (en) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CA3094527A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CN114174273A (zh) * | 2019-03-22 | 2022-03-11 | 优曼尼蒂治疗公司 | 化合物和其用途 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN115427050B (zh) * | 2020-02-07 | 2025-02-14 | 南佛罗里达大学 | 对tau蛋白病中的β-抑制蛋白寡聚化的抑制 |
| WO2022104011A1 (en) * | 2020-11-12 | 2022-05-19 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| MA71666A (fr) * | 2021-03-18 | 2025-05-30 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés |
| CN115607547A (zh) * | 2021-07-14 | 2023-01-17 | 厦门大学 | 一种睑板腺功能障碍动物模型的造模药物、构建方法与应用 |
| WO2024181431A1 (ja) * | 2023-02-28 | 2024-09-06 | 国立大学法人 長崎大学 | タンパク質凝集体の分解促進用組成物、およびタンパク質凝集体形成を伴う神経変性疾患の予防または治療用医薬組成物 |
Family Cites Families (285)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4782071A (en) | 1986-11-03 | 1988-11-01 | Warner-Lambert Company | Tetrasubstituted urea cholinergic agents |
| CA2184919C (en) | 1995-01-11 | 2000-03-14 | Eui-Hwan Cho | New piperazine derivatives and methods for the preparation thereof and compositions containing the same |
| TW360653B (en) | 1995-03-01 | 1999-06-11 | Janssen Pharmaceutica Nv | A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition |
| AU4414999A (en) | 1998-06-08 | 1999-12-30 | Sambasiva R. Chavali | Inhibition of delta-9-desaturase activity by saponins |
| US6107313A (en) | 1998-10-02 | 2000-08-22 | Combichem, Inc. | Dopamine receptor antagonists |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20070087363A1 (en) | 1998-12-22 | 2007-04-19 | Myriad Genetics, Incorporated | Therapeutic methods, compounds and compositions |
| MXPA02000253A (es) | 1999-07-01 | 2002-06-21 | Ajinomoto Kk | Compuestos heterociclicos y uso medico de los mismos. |
| JP2003528806A (ja) | 1999-07-20 | 2003-09-30 | ダウ・アグロサイエンス・エル・エル・シー | 殺菌・殺カビ性複素環式芳香族アミドおよびそれらの組成物、使用および製造方法 |
| BR0013469B1 (pt) | 1999-08-20 | 2011-01-25 | amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica. | |
| PT1315831E (pt) | 2000-02-24 | 2010-11-04 | Xenon Pharmaceuticals Inc | Estearoil-coa dessaturase para identificar agentes terapêuticos que reduzem triglicéridos |
| PT1300396E (pt) | 2000-06-12 | 2009-04-20 | Eisai R&D Man Co Ltd | Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização |
| WO2001095856A2 (en) | 2000-06-15 | 2001-12-20 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
| DE60134995D1 (de) | 2000-09-26 | 2008-09-04 | Xenon Pharmaceuticals Inc | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden |
| EP1346042A2 (en) | 2000-11-17 | 2003-09-24 | Xenon Genetics, Inc. | Fat regulated genes, uses thereof, and compounds for modulating same |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| CA2438661C (en) | 2001-02-15 | 2011-05-31 | University Of Chicago | Yeast screens for agents affecting protein folding |
| MXPA03010269A (es) | 2001-05-11 | 2004-05-05 | Vertex Pharma | Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38. |
| US20050256068A1 (en) | 2001-05-18 | 2005-11-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) |
| US20050043256A1 (en) | 2001-07-30 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
| US6727247B2 (en) | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| AU2003215203A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Short interfering nucleic acid inhibition of stearoyl-coa desaturase (scd) gene |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| WO2004014902A2 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| WO2004014892A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| AU2003303373B8 (en) | 2002-12-18 | 2010-06-10 | Cytovia, Inc. | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| EP1635800A2 (en) | 2003-06-10 | 2006-03-22 | Kalypsys, Inc. | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
| ES2386354T3 (es) | 2003-07-29 | 2012-08-17 | Xenon Pharmaceuticals Inc. | Derivados de piridilo y su uso como agentes terapéuticos |
| JP4782008B2 (ja) | 2003-07-30 | 2011-09-28 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピリジル誘導体および治療剤としてのその用途 |
| US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7456180B2 (en) | 2003-07-30 | 2008-11-25 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| EP3042895A1 (en) | 2003-07-30 | 2016-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| AU2004261249B2 (en) | 2003-07-30 | 2008-09-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| CA2534529A1 (en) | 2003-08-06 | 2005-02-24 | Pfizer Products Inc. | Oxazole compounds for the treatment of neurodegenerative disorders |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| DE602004008658T2 (de) | 2003-09-05 | 2008-06-12 | Cellzome Ag | Behandlung neurodegenerativer krankheiten |
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| US8188064B2 (en) | 2003-11-25 | 2012-05-29 | Wisconsin Alumni Research Foundation | Vitamin D analogs for obesity prevention and treatment |
| US7452670B2 (en) | 2003-12-04 | 2008-11-18 | University Of Washington | Methods of identifying agents that diminish cellular toxicity associated with an α-synuclein polypeptide of Parkinson's disease in yeast |
| BRPI0418149A (pt) | 2003-12-24 | 2007-04-17 | Prosidion Ltd | derivados heterocìclicos como agonistas do receptor de gprc |
| JP2005213233A (ja) | 2004-02-02 | 2005-08-11 | Fuji Oil Co Ltd | 肝臓ステアロイル‐ＣｏＡ不飽和化酵素１合成抑制剤 |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| WO2006012325A1 (en) | 2004-06-25 | 2006-02-02 | E.I. Dupont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
| BRPI0418939A (pt) | 2004-07-06 | 2008-04-08 | Xenon Pharmaceuticals Inc | derivados de nicotinamida e sua utilização como agentes terapêuticos |
| ES2325836T3 (es) | 2004-07-26 | 2009-09-21 | Merck Serono Sa | Derivados de la n.hidroxiamida y uso de los mismos. |
| CA2575300A1 (en) | 2004-08-09 | 2006-02-16 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of degs inhibitors |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| US20080167321A1 (en) | 2004-09-20 | 2008-07-10 | Xenon Pharmaceuticals Inc. | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase |
| JP4958786B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| MX2007003319A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
| US7547698B2 (en) | 2004-09-20 | 2009-06-16 | Xenon Pharmaceuticals Inc. | Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD) |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| EP1799667B1 (en) | 2004-09-20 | 2013-03-20 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| KR101368228B1 (ko) | 2004-11-10 | 2014-02-27 | 인사이트 코포레이션 | 락탐 화합물 및 약제로서의 이의 용도 |
| US8399438B2 (en) | 2004-11-22 | 2013-03-19 | Wisconsin Alumni Research Foundation | 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and its uses |
| US20060167044A1 (en) | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
| WO2006067531A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| CN101128435A (zh) | 2004-12-27 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体激动剂用于治疗神经病学及精神病学病症的吡唑酮化合物 |
| EP1836179B1 (en) | 2004-12-30 | 2015-05-06 | Janssen Pharmaceutica NV | Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
| AU2005324024B2 (en) | 2005-01-07 | 2011-02-17 | F. Hoffmann-La Roche Ag | [4-(Heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| GT200600046A (es) | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| WO2006125181A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
| WO2006125179A1 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| WO2007046868A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Thiazolidine derivatives and their uses as therapeutic agents |
| WO2006125194A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| BRPI0611187A2 (pt) | 2005-06-03 | 2010-08-24 | Xenon Pharmaceuticals Inc | derivados aminotiazàis como inibidores da estearoil-coa desaturase humana |
| CA2610196A1 (en) | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JPWO2006137465A1 (ja) | 2005-06-24 | 2009-01-22 | 塩野義製薬株式会社 | 含窒素複素環誘導体 |
| US20090118296A1 (en) * | 2005-07-20 | 2009-05-07 | Merck Frosst Canada Ltd. | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase |
| EP1951731A4 (en) | 2005-11-15 | 2010-07-07 | Merck Frosst Canada Ltd | AZACYCLOHEXANDERIVATES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| MX2008008529A (es) | 2005-12-29 | 2008-09-26 | Organon Nv | Inhibidores de amida hidrolasa de acido graso. |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| WO2007136746A2 (en) | 2006-05-19 | 2007-11-29 | Xenon Pharmaceuticals Inc. | Macrocyclic compounds and their uses as stearoyl-coa desaturase |
| WO2007134457A1 (en) | 2006-05-22 | 2007-11-29 | Merck Frosst Canada Ltd. | Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CL2007001597A1 (es) | 2006-06-05 | 2008-05-16 | Novartis Ag Xenon Pharmaceutic | Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes |
| CA2654792A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2009539885A (ja) | 2006-06-13 | 2009-11-19 | メルク フロスト カナダ リミテツド | ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体 |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008003753A1 (en) | 2006-07-07 | 2008-01-10 | Biovitrum Ab (Publ) | Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity |
| WO2008008852A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
| JP2009543802A (ja) | 2006-07-11 | 2009-12-10 | エモリー・ユニバーシテイ | 医学的疾患の治療のためのジアジン及びトリアジン構造を含むｃｘｃｒ４アンタゴニスト |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| WO2008017161A1 (en) | 2006-08-09 | 2008-02-14 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2008127349A2 (en) | 2006-08-15 | 2008-10-23 | Novartis Ag | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level |
| WO2008024139A2 (en) | 2006-08-18 | 2008-02-28 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
| WO2008023720A1 (en) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| RU2009110254A (ru) | 2006-08-24 | 2010-09-27 | Новартис АГ (CH) | Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений |
| WO2008029266A1 (en) | 2006-09-08 | 2008-03-13 | Glenmark Pharmaceuticals S.A. | Stearoyl coa desaturase inhibitors |
| CN101516877B (zh) | 2006-09-22 | 2013-09-11 | 诺瓦提斯公司 | 杂环有机化合物 |
| CN101522676A (zh) | 2006-10-05 | 2009-09-02 | Cv医药有限公司 | 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物 |
| US7893066B2 (en) | 2006-10-05 | 2011-02-22 | Gilead Palo Alto, Inc. | Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors |
| WO2008044767A1 (en) | 2006-10-13 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Aromatic amine derivative and use thereof |
| SI2076508T1 (sl) | 2006-10-18 | 2011-04-29 | Pfizer Prod Inc | Spojine biaril eter sečnine |
| AU2007312866A1 (en) | 2006-10-20 | 2008-04-24 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| WO2008056687A1 (en) | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Novel spiropiperidine derivative |
| JP2010510201A (ja) | 2006-11-20 | 2010-04-02 | グレンマーク・ファーマシューティカルズ・エスエー | ステアリン酸ＣｏＡ脱飽和酵素阻害剤としてのアセチレン誘導体 |
| BRPI0719379A2 (pt) | 2006-11-24 | 2014-02-11 | Ac Immune Sa | Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste |
| CN101589039B (zh) | 2006-12-01 | 2012-09-05 | 默克弗罗斯特加拿大有限公司 | 作为硬脂酰辅酶a △-9去饱和酶抑制剂的氮杂环烷衍生物 |
| TW200826936A (en) * | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CN101562977A (zh) | 2006-12-15 | 2009-10-21 | 艾博特公司 | 新的二唑化合物 |
| EP2121671A1 (en) | 2006-12-20 | 2009-11-25 | Novartis AG | 2-substituted 5-membered heterocycles as scd inhibitors |
| GB0625605D0 (en) | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| AU2007336781C1 (en) | 2006-12-21 | 2014-10-09 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| GB0625654D0 (en) | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| GB0625604D0 (en) * | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| GB0625594D0 (en) | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| US8575167B2 (en) | 2007-02-06 | 2013-11-05 | Takeda Pharmaceutical Company Limited | Spiro compounds having stearoyl-CoA desaturase action |
| US20100120669A1 (en) | 2007-02-28 | 2010-05-13 | Anne Marie Jeanne Bouillot | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase |
| EP2137187A1 (en) | 2007-03-28 | 2009-12-30 | Inovacia AB | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| WO2008120759A1 (ja) | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ウレア化合物およびその用途 |
| WO2008120744A1 (ja) | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ５員環アミド化合物およびその用途 |
| WO2008123469A1 (ja) | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | ６員環アミド化合物およびその用途 |
| JP2010523653A (ja) | 2007-04-09 | 2010-07-15 | ギリアード・パロ・アルト・インコーポレイテッド | ステアロイルＣｏＡデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体 |
| US20080255161A1 (en) | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| CA2683948A1 (en) | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2008139845A1 (ja) | 2007-04-24 | 2008-11-20 | Daiichi Sankyo Company, Limited | 新規アミド誘導体 |
| US20100152208A1 (en) | 2007-05-23 | 2010-06-17 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| JP2009019013A (ja) * | 2007-07-12 | 2009-01-29 | Daiichi Sankyo Co Ltd | 新規ヘテロアリールピペリジン誘導体 |
| GB0714129D0 (en) | 2007-07-19 | 2007-08-29 | Smithkline Beecham Corp | compounds |
| JP2010533658A (ja) | 2007-07-20 | 2010-10-28 | メルク フロスト カナダ リミテツド | ステアロイル補酵素ａデルタ−９デサチュラーゼ阻害剤としての二環性へテロ芳香族化合物 |
| GB0715055D0 (en) | 2007-08-02 | 2007-09-12 | Smithkline Beecham Corp | Compounds |
| ES2352098T3 (es) | 2007-08-08 | 2011-02-15 | Graceway Pharmaceuticals, Llc | Derivado de fenoxi-pirrolidina y su uso y composiciones. |
| DE602008005894D1 (de) | 2007-08-14 | 2011-05-12 | Bayer Schering Pharma Ag | Kondensierte imidazole zur krebsbehandlung |
| CA2697551C (en) | 2007-09-20 | 2013-03-12 | Irm Llc | Piperidine derivatives as modulators of gpr119 activity |
| WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| GB0721419D0 (en) | 2007-10-31 | 2007-12-12 | Smithkline Beecham Corp | Compounds |
| GB0722075D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| WO2009070533A1 (en) | 2007-11-29 | 2009-06-04 | Complegen, Inc. | Methods of inhibiting steroyl coa desaturase |
| AU2008334705B2 (en) | 2007-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Inhibitors of stearoyl-CoA desaturase |
| WO2009073973A1 (en) | 2007-12-11 | 2009-06-18 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| ES2387714T3 (es) | 2007-12-28 | 2012-09-28 | Wisconsin Alumni Research Foundation | Análogos de 2-metilen-20-metil-19,24,25,26,27-pentanor-vitamina D |
| KR101584826B1 (ko) | 2008-02-20 | 2016-01-18 | 노파르티스 아게 | 스테아로일-ＣｏＡ 데새투라제의 헤테로시클릭 억제제 |
| JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒ修飾因子としてのへテロアリール誘導体 |
| NZ588634A (en) | 2008-03-20 | 2012-03-30 | Forest Lab Holdings Ltd | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| KR20100134680A (ko) | 2008-03-20 | 2010-12-23 | 포레스트 래보러토리즈 홀딩스 리미티드 | 스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체 |
| DK2615085T3 (en) | 2008-03-31 | 2015-10-05 | Vertex Pharma | Pyridyl derivatives as CFTR modulators |
| JP2011516498A (ja) | 2008-04-04 | 2011-05-26 | ギリアード サイエンシーズ， インコーポレイテッド | ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するためのトリアゾロピリジノン誘導体 |
| CA2719362A1 (en) | 2008-04-04 | 2009-10-08 | Gilead Sciences, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| JP2011516494A (ja) | 2008-04-07 | 2011-05-26 | ギリアード サイエンシーズ， インコーポレイテッド | ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための２Ｈ−ベンゾ［ｂ］［１，４］オキサジン−３（４Ｈ）−オン誘導体 |
| EP2279177A1 (en) | 2008-04-22 | 2011-02-02 | Merck Frosst Canada Ltd. | Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB0810913D0 (en) | 2008-06-13 | 2008-07-23 | Smithkline Beecham Corp | Comppounds |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| MX2010014572A (es) | 2008-06-27 | 2011-03-24 | Novartis Ag | Compuestos organicos. |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| WO2010007482A2 (en) | 2008-07-16 | 2010-01-21 | Glenmark Pharmaceuticals S.A. | Thiazole derivatives as stearoyl coa desaturase inhibitors |
| GB0813740D0 (en) | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
| JP2010043052A (ja) | 2008-08-18 | 2010-02-25 | Mitsubishi Chemicals Corp | カロテノイド類の分離方法 |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| JP2012501975A (ja) | 2008-09-08 | 2012-01-26 | メルク カナダ インコーポレイテッド | ステアロイルコエンザイムＡδ−９デサチュラーゼの阻害剤としての芳香族複素環化合物 |
| WO2010028761A1 (de) | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
| WO2010039186A2 (en) | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| US20110184027A1 (en) | 2008-09-25 | 2011-07-28 | Glenmark Pharmaceuticals S.A. | Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification |
| WO2010037225A1 (en) | 2008-10-02 | 2010-04-08 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20100267752A1 (en) | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20100267748A1 (en) | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS |
| CA2740389A1 (en) | 2008-10-15 | 2010-05-20 | Gilead Sciences, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
| EP2350054A4 (en) | 2008-10-17 | 2012-03-28 | Merck Canada Inc | AZETIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2192196A1 (en) | 2008-11-27 | 2010-06-02 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Prediction of lipid-metabotype-related physiological susceptibilities |
| US20100160323A1 (en) | 2008-12-23 | 2010-06-24 | Alexander Bischoff | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE |
| WO2010094120A1 (en) | 2009-02-17 | 2010-08-26 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2012518603A (ja) | 2009-02-23 | 2012-08-16 | メルク カナダ インコーポレイテッド | ステアロイル−コエンザイムａデルタ−９デサチュラーゼの阻害剤としての複素環誘導体 |
| US8901306B2 (en) | 2009-03-02 | 2014-12-02 | Stemsynergy Therapeutics, Inc. | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell |
| EP2404902A1 (en) | 2009-03-05 | 2012-01-11 | Shionogi&Co., Ltd. | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
| US20120010186A1 (en) | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP2414366A1 (en) | 2009-04-01 | 2012-02-08 | Novartis AG | Spiro derivatives for the modulation of stearoyl-coa desaturase |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011872A1 (en) | 2009-07-28 | 2011-02-03 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| FR2948939B1 (fr) | 2009-08-05 | 2013-03-22 | Pf Medicament | Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine |
| US8354403B2 (en) | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| RU2569063C2 (ru) | 2009-09-01 | 2015-11-20 | Катабэйсис Фармасьютикалз, Инк. | Конъюгаты жирных кислот и ниацина и их применение |
| EP2475367A1 (en) | 2009-09-10 | 2012-07-18 | Centre National De La Recherche Scientifique | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES |
| EP2483264A1 (en) | 2009-10-01 | 2012-08-08 | Novartis AG | Pyrazole derivatives which modulate stearoyl-coa desaturase |
| WO2011047481A1 (en) | 2009-10-23 | 2011-04-28 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| BR112012015248B1 (pt) | 2009-12-23 | 2022-01-04 | Jasco Pharmaceuticals, LLC | Composto |
| KR101939704B1 (ko) | 2010-03-01 | 2019-01-17 | 지티엑스, 인코포레이티드 | 암 치료용 화합물 |
| WO2011123681A1 (en) | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| WO2012046681A1 (ja) | 2010-10-04 | 2012-04-12 | 興和株式会社 | 脂質代謝関連ｍＲＮＡの発現抑制剤 |
| FR2958935B1 (fr) | 2010-04-19 | 2012-06-22 | Pf Medicament | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine |
| EP2582681A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| KR101764952B1 (ko) | 2010-07-29 | 2017-08-03 | 리겔 파마슈티칼스, 인크. | Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법 |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| CA2812081A1 (en) | 2010-09-13 | 2012-03-22 | Novartis Ag | Triazine-oxadiazoles |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| WO2012066077A1 (en) | 2010-11-18 | 2012-05-24 | Prosidion Limited | 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders |
| EP2455080A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| EP2455081A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| US20140031547A1 (en) | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
| EP2651930B1 (en) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| US8853213B2 (en) | 2011-01-03 | 2014-10-07 | Hanmi Pharm. Co., Ltd | Bicyclic compound for modulating G protein-coupled receptors |
| US8822471B2 (en) | 2011-03-14 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| EP2694482A1 (en) | 2011-04-04 | 2014-02-12 | Siena Biotech S.p.A. | Wnt pathway antagonists |
| CA2833507A1 (en) | 2011-06-07 | 2012-12-13 | Dainippon Sumitomo Pharma Co., Ltd. | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| ES2540956T3 (es) | 2011-07-01 | 2015-07-15 | Remynd Nv | Derivados de 1,2,4-tiadiazol-5-ilpiperazina útiles en el tratamiento de enfermedades neurodegenerativas |
| BR112014003963A2 (pt) | 2011-09-01 | 2017-03-21 | Irm Llc | compostos e composições como inibidores de quinase c-kit |
| AU2012313888B2 (en) | 2011-09-27 | 2016-03-31 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| MX2014004426A (es) | 2011-10-15 | 2014-07-09 | Genentech Inc | Metodos de uso de antagonistas de scd1. |
| WO2013070660A1 (en) | 2011-11-07 | 2013-05-16 | Emory University | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction |
| US9238658B2 (en) | 2011-12-06 | 2016-01-19 | Janssen Pharmaceutica Nv | Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors |
| WO2013085957A1 (en) | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors |
| US8530461B2 (en) | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
| US20130225529A1 (en) | 2012-02-27 | 2013-08-29 | Basil Rigas | Phospho-ester derivatives and uses thereof |
| US9233102B2 (en) | 2012-03-07 | 2016-01-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US20150290265A1 (en) | 2012-04-23 | 2015-10-15 | Piramal Enterprises Limited | Composition for treating metabolic disorders |
| WO2013170072A2 (en) | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| WO2013175474A2 (en) | 2012-05-22 | 2013-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Selective inhibitors of undifferentiated cells |
| WO2014003153A1 (ja) | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| WO2014065860A1 (en) | 2012-10-24 | 2014-05-01 | The General Hospital Corporation | Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions |
| WO2014086704A1 (en) | 2012-12-03 | 2014-06-12 | F. Hoffmann-La Roche Ag | Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1) |
| CN104822420A (zh) | 2012-12-03 | 2015-08-05 | 霍夫曼-拉罗奇有限公司 | 作为scd1的抑制剂的取代的异噁唑胺类化合物 |
| JP2016028016A (ja) | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
| US9416102B2 (en) | 2013-01-23 | 2016-08-16 | Wisconsin Alumni Research Foundation | (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs |
| TWI594975B (zh) | 2013-04-24 | 2017-08-11 | 第一三共股份有限公司 | 二羧酸化合物 |
| KR101524650B1 (ko) | 2013-07-30 | 2015-06-03 | 경상대학교산학협력단 | 테트라하이드로이소퀴놀린 알칼로이드계 화합물 ｙｓ－５１ｓ를 포함하는 대사성 질환의 예방 및 치료용 조성물 |
| KR20150015305A (ko) | 2013-07-31 | 2015-02-10 | 안동대학교 산학협력단 | 주박 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| CN104163794A (zh) | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
| CA2935103C (en) | 2013-12-31 | 2018-08-28 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| CA2937989A1 (en) | 2014-01-29 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| GB201403969D0 (en) | 2014-03-06 | 2014-04-23 | Isis Innovation | Compounds for use in controlling body fat |
| US20170015654A1 (en) | 2014-03-12 | 2017-01-19 | Takeda Pharmaceutical Company Limited | Pyridazine compound |
| EP3119774A1 (en) | 2014-03-17 | 2017-01-25 | reMynd NV | Oxadiazole compounds |
| WO2016022626A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP4180041A1 (en) | 2014-08-07 | 2023-05-17 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| KR101715449B1 (ko) | 2014-08-13 | 2017-03-30 | 주식회사 큐리언트 | 염증성 질환 치료용 화합물 |
| EP3842514A1 (en) | 2014-09-12 | 2021-06-30 | Whitehead Institute for Biomedical Research | Cells expressing apolipoprotein e and uses thereof |
| US10662164B2 (en) | 2014-09-25 | 2020-05-26 | University Of Notre Dame Du Lac | Non-beta lactam antibiotics |
| EP3034500A1 (en) | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| CN105753814A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| US20160223559A1 (en) | 2015-02-02 | 2016-08-04 | The Regents Of The University Of California | Tetrazine-containing compounds and synthetic methods thereof |
| EP3257510B1 (en) | 2015-02-09 | 2021-10-20 | National University Corporation Okayama University | Lactate dehydrogenase inhibitor and antiepileptic drug containing same |
| CN106146391A (zh) | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
| US20180305334A1 (en) | 2015-10-14 | 2018-10-25 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| US20200262799A1 (en) | 2015-11-30 | 2020-08-20 | Universite De Bourgogne | Process for preparing functionalized 1,2,4,5-tetrazine compounds |
| JP7114076B2 (ja) | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| KR20190015748A (ko) | 2016-06-08 | 2019-02-14 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Atf4 경로 억제제로서의 화학적 화합물 |
| US20190185567A1 (en) | 2016-08-01 | 2019-06-20 | Ignyta, Inc. | Combinations for the treatment of cancer |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| US11135207B2 (en) | 2016-12-13 | 2021-10-05 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| CA3049010A1 (en) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| EP3589659B1 (en) | 2017-02-28 | 2025-04-09 | Mayo Foundation for Medical Education and Research | Combinations for use in the treatment of cancer |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| EP3381908A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| WO2019018795A1 (en) | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | COMPOUNDS AND USES THEREOF |
| CA3083000A1 (en) * | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EP3728200A1 (en) | 2017-12-21 | 2020-10-28 | Gliapharm SA | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| JP2021507945A (ja) | 2017-12-21 | 2021-02-25 | グリアファーム エスエー | 認知症を含む神経障害のための組成物および治療方法 |
| KR20250057925A (ko) | 2018-01-11 | 2025-04-29 | 켄타우루스 테라퓨틱스 | 질병 치료를 위한 디하이드로세라마이드 불포화화효소의 저해제 |
| US12023332B2 (en) | 2018-03-05 | 2024-07-02 | Wylder Nation Foundation | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin |
| CA3094527A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| WO2019209962A1 (en) | 2018-04-25 | 2019-10-31 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2019209948A1 (en) | 2018-04-25 | 2019-10-31 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| MX2021000881A (es) | 2018-07-24 | 2021-06-08 | Epizyme Inc | Compuestos de piridin-2-ona utiles como antagonistas de smarca2. |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CN114174273A (zh) | 2019-03-22 | 2022-03-11 | 优曼尼蒂治疗公司 | 化合物和其用途 |
| CA3159766A1 (en) | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Mrgprx2 antagonists for the treatment of inflammatory disorders |
| CA3159628A1 (en) | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Mrgprx2 antagonists and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| TW202136238A (zh) | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
| WO2021154571A1 (en) | 2020-01-31 | 2021-08-05 | American Sterilizer Company | Surgical light head with beam spreading and adjustable power balancing |
-
2018
- 2018-01-05 CA CA3049010A patent/CA3049010A1/en active Pending
- 2018-01-05 JP JP2019536521A patent/JP2020514293A/ja active Pending
- 2018-01-05 EP EP18735798.3A patent/EP3566055B1/en active Active
- 2018-01-05 IL IL304017A patent/IL304017A/en unknown
- 2018-01-05 CN CN201880016244.5A patent/CN110392833A/zh active Pending
- 2018-01-05 US US15/863,773 patent/US10973810B2/en active Active
- 2018-01-05 ES ES18735798T patent/ES3025460T3/es active Active
- 2018-01-05 BR BR112019013954-0A patent/BR112019013954A2/pt unknown
- 2018-01-05 MA MA047212A patent/MA47212A/fr unknown
- 2018-01-05 KR KR1020197022664A patent/KR20190108118A/ko not_active Ceased
- 2018-01-05 MX MX2019008124A patent/MX2019008124A/es unknown
- 2018-01-05 AU AU2018205275A patent/AU2018205275B2/en active Active
- 2018-01-05 EA EA201991650A patent/EA201991650A1/ru unknown
- 2018-01-05 WO PCT/US2018/012697 patent/WO2018129403A1/en not_active Ceased
-
2019
- 2019-07-03 IL IL267818A patent/IL267818A/en unknown
-
2021
- 2021-04-09 US US17/226,233 patent/US12433880B2/en active Active
-
2022
- 2022-12-19 JP JP2022201688A patent/JP2023036752A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL267818A (en) | 2019-09-26 |
| JP2020514293A (ja) | 2020-05-21 |
| MA47212A (fr) | 2019-11-13 |
| US20220040167A1 (en) | 2022-02-10 |
| WO2018129403A1 (en) | 2018-07-12 |
| AU2018205275B2 (en) | 2024-05-02 |
| CA3049010A1 (en) | 2018-07-12 |
| KR20190108118A (ko) | 2019-09-23 |
| JP2023036752A (ja) | 2023-03-14 |
| EP3566055A1 (en) | 2019-11-13 |
| MX2019008124A (es) | 2019-12-05 |
| AU2018205275A1 (en) | 2019-07-25 |
| EP3566055B1 (en) | 2025-03-12 |
| EP3566055C0 (en) | 2025-03-12 |
| EP3566055A4 (en) | 2020-12-02 |
| US10973810B2 (en) | 2021-04-13 |
| US20180193325A1 (en) | 2018-07-12 |
| IL304017A (en) | 2023-08-01 |
| CN110392833A (zh) | 2019-10-29 |
| US12433880B2 (en) | 2025-10-07 |
| EA201991650A1 (ru) | 2020-01-20 |
| ES3025460T3 (en) | 2025-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3025460T3 (en) | Scd inhibitor for the treatment of neurological disorders | |
| US11136317B2 (en) | NADPH oxidase 4 inhibitors | |
| DK2935244T3 (en) | UNTIL UNKNOWN BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | |
| AU2017258781C1 (en) | Di-substituted pyrazole compounds for the treatment of diseases | |
| BR112014026643B1 (pt) | Derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta, seus usos e composição farmacêutica | |
| BR112015027964B1 (pt) | Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística | |
| ES2955206T3 (es) | Derivados de espiroquinoxalina como inhibidores de la muerte celular regulada no apoptótica | |
| KR20060101546A (ko) | 바소프레신 길항제로서의 트리아졸 유도체 | |
| JP2022546717A (ja) | Ｕｓｐ３０阻害剤としての活性を有する置換シアノピロリジン類 | |
| CA3083000A1 (en) | Compounds and uses thereof | |
| WO2019209948A9 (en) | Compounds and uses thereof | |
| US20230374143A1 (en) | A sortilin antagonist for use in the prevention or treatment of hearing loss | |
| EP4161926A1 (en) | Pyridopyrimidines and methods of their use | |
| US20250034122A1 (en) | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors | |
| US20170057955A1 (en) | Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | |
| ES2700448A2 (es) | Uso de ligandos del receptor sigma en la diabetes y el sindrome metabolico | |
| ES2659828A2 (es) | Uso de los derivados 4H-pirano[2,3-c] pirazol en el tratamiento de enfermedades neurodegenerativas | |
| MXPA06006155A (es) | Derivados de triazol como antagonistas de vasopresina | |
| HK1136563A (en) | Indole compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: YUMANITY, INC. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: YUMANITY, INC. (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: JANSSEN PHARMACEUTICA NV (BE) |